Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-drug and Extensively Drug Resistant Tuberculosis

Overview

Journal PLoS Comput Biol

Specialty Biology

Date 2009 Jul 7

PMID 19578428

Citations 129

Authors

Sarah L Kinnings

Nina Liu

Nancy Buchmeier

Peter J Tonge

Lei Xie

Philip E Bourne

Affiliations

Soon will be listed here.

Abstract

The rise of multi-drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis around the world, including in industrialized nations, poses a great threat to human health and defines a need to develop new, effective and inexpensive anti-tubercular agents. Previously we developed a chemical systems biology approach to identify off-targets of major pharmaceuticals on a proteome-wide scale. In this paper we further demonstrate the value of this approach through the discovery that existing commercially available drugs, prescribed for the treatment of Parkinson's disease, have the potential to treat MDR and XDR tuberculosis. These drugs, entacapone and tolcapone, are predicted to bind to the enzyme InhA and directly inhibit substrate binding. The prediction is validated by in vitro and InhA kinetic assays using tablets of Comtan, whose active component is entacapone. The minimal inhibition concentration (MIC(99)) of entacapone for Mycobacterium tuberculosis (M.tuberculosis) is approximately 260.0 microM, well below the toxicity concentration determined by an in vitro cytotoxicity model using a human neuroblastoma cell line. Moreover, kinetic assays indicate that Comtan inhibits InhA activity by 47.0% at an entacapone concentration of approximately 80 microM. Thus the active component in Comtan represents a promising lead compound for developing a new class of anti-tubercular therapeutics with excellent safety profiles. More generally, the protocol described in this paper can be included in a drug discovery pipeline in an effort to discover novel drug leads with desired safety profiles, and therefore accelerate the development of new drugs.

Citing Articles

Better understanding the phenotypic effects of drugs through shared targets in genetic disease networks.

Diaz-Santiago E, Moya-Garcia A, Perez-Garcia J, Yahyaoui R, Orengo C, Pazos F Front Pharmacol. 2025; 15:1470931.

PMID: 39911831 PMC: 11794328. DOI: 10.3389/fphar.2024.1470931.

Non-Negative Matrix Tri-Factorization for Representation Learning in Multi-Omics Datasets with Applications to Drug Repurposing and Selection.

Messa L, Testa C, Carelli S, Rey F, Jacchetti E, Cereda C Int J Mol Sci. 2024; 25(17).

PMID: 39273521 PMC: 11394968. DOI: 10.3390/ijms25179576.

Synthesis, crystal structure, biological and docking studies of 5-hydroxy-2-{[(2-methylpropyl)iminio]methyl}phenolate.

Arjunan A, Sebastian A Future Med Chem. 2024; 16(19):1983-1997.

PMID: 39258968 PMC: 11486094. DOI: 10.1080/17568919.2024.2389763.

Tackling Antibiotic Resistance: Exploring 5-Fluorouracil as a Promising Antimicrobial Strategy for the Treatment of Infection.

Zuo J, Quan Y, Li J, Li Y, Song D, Li X Animals (Basel). 2024; 14(9).

PMID: 38731290 PMC: 11083182. DOI: 10.3390/ani14091286.

Systems biology approaches to identify driver genes and drug combinations for treating COVID-19.

Ebrahimi A, Roshani F Sci Rep. 2024; 14(1):2257.

PMID: 38278931 PMC: 10817985. DOI: 10.1038/s41598-024-52484-8.

References

Amaro R, Baron R, McCammon J . An improved relaxed complex scheme for receptor flexibility in computer-aided drug design. J Comput Aided Mol Des. 2008; 22(9):693-705. PMC: 2516539. DOI: 10.1007/s10822-007-9159-2. View

He X, Alian A, Stroud R, de Montellano P . Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. J Med Chem. 2006; 49(21):6308-23. PMC: 2517584. DOI: 10.1021/jm060715y. View

Hopkins A . Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008; 4(11):682-90. DOI: 10.1038/nchembio.118. View

Nwaka S, Hudson A . Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov. 2006; 5(11):941-55. DOI: 10.1038/nrd2144. View

Wermuth C . Selective optimization of side activities: the SOSA approach. Drug Discov Today. 2006; 11(3-4):160-4. DOI: 10.1016/S1359-6446(05)03686-X. View

Tervo A, Nyronen T, Ronkko T, Poso A . A structure-activity relationship study of catechol-O-methyltransferase inhibitors combining molecular docking and 3D QSAR methods. J Comput Aided Mol Des. 2004; 17(12):797-810. DOI: 10.1023/b:jcam.0000021831.47952.a7. View

Altschul S, Madden T, Schaffer A, Zhang J, Zhang Z, Miller W . Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997; 25(17):3389-402. PMC: 146917. DOI: 10.1093/nar/25.17.3389. View

He X, Alian A, de Montellano P . Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorg Med Chem. 2007; 15(21):6649-58. PMC: 2020492. DOI: 10.1016/j.bmc.2007.08.013. View

Kuo M, Morbidoni H, Alland D, Sneddon S, Gourlie B, Staveski M . Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data. J Biol Chem. 2003; 278(23):20851-9. DOI: 10.1074/jbc.M211968200. View

10.

Seefeld M, Miller W, Newlander K, Burgess W, DeWolf Jr W, Elkins P . Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J Med Chem. 2003; 46(9):1627-35. DOI: 10.1021/jm0204035. View

11.

Rozwarski D, Vilcheze C, Sugantino M, Bittman R, Sacchettini J . Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate. J Biol Chem. 1999; 274(22):15582-9. DOI: 10.1074/jbc.274.22.15582. View

12.

Weber A, Casini A, Heine A, Kuhn D, Supuran C, Scozzafava A . Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem. 2004; 47(3):550-7. DOI: 10.1021/jm030912m. View

13.

Dorman S, Chaisson R . From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med. 2007; 13(3):295-8. DOI: 10.1038/nm0307-295. View

14.

Xie L, Bourne P . Detecting evolutionary relationships across existing fold space, using sequence order-independent profile-profile alignments. Proc Natl Acad Sci U S A. 2008; 105(14):5441-6. PMC: 2291117. DOI: 10.1073/pnas.0704422105. View

15.

Zsoldos Z, Reid D, Simon A, Sadjad S, Johnson A . eHiTS: a new fast, exhaustive flexible ligand docking system. J Mol Graph Model. 2006; 26(1):198-212. DOI: 10.1016/j.jmgm.2006.06.002. View

16.

Zimmermann G, Lehar J, Keith C . Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007; 12(1-2):34-42. DOI: 10.1016/j.drudis.2006.11.008. View

17.

Korlipara L, Cooper J, Schapira A . Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells. Neuropharmacology. 2004; 46(4):562-9. DOI: 10.1016/j.neuropharm.2003.10.015. View

18.

Miller W, Seefeld M, Newlander K, Uzinskas I, Burgess W, Heerding D . Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J Med Chem. 2002; 45(15):3246-56. DOI: 10.1021/jm020050+. View

19.

Banerjee A, DUBNAU E, Quemard A, Balasubramanian V, Um K, Wilson T . inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 1994; 263(5144):227-30. DOI: 10.1126/science.8284673. View

20.

Sullivan T, Truglio J, Boyne M, Novichenok P, Zhang X, Stratton C . High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem Biol. 2006; 1(1):43-53. DOI: 10.1021/cb0500042. View